Top Page
Austco Healthcare Limited
(Sydney:AHC)
Austco Healthcare Limited (AHC) vs. iShares MSCI Australia ETF (EWA)
Austco Healthcare Limited Business Overview & Revenue Model
Austco Healthcare Limited Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 72.22M | 81.41M | 58.15M | 41.98M | 35.88M | 31.25M |
| Gross Profit | 37.67M | 42.37M | 30.67M | 6.68M | 18.85M | 16.71M |
| EBITDA | 10.64M | 11.10M | 8.11M | 3.60M | 3.52M | 3.13M |
| Net Income | 8.84M | 5.93M | 7.08M | 2.26M | 2.33M | 3.42M |
Balance Sheet | ||||||
| Total Assets | 74.28M | 91.07M | 68.70M | 37.85M | 34.03M | 27.18M |
| Cash, Cash Equivalents and Short-Term Investments | 14.91M | 14.48M | 13.56M | 4.67M | 7.63M | 7.77M |
| Total Debt | 2.24M | 3.88M | 1.78M | 524.00K | 979.00K | 1.15M |
| Total Liabilities | 25.17M | 39.34M | 24.33M | 12.85M | 10.94M | 7.88M |
| Stockholders Equity | 49.11M | 51.73M | 44.38M | 25.00M | 23.09M | 19.30M |
Cash Flow | ||||||
| Free Cash Flow | 10.14M | 10.66M | 7.45M | -1.25M | 315.00K | 1.91M |
| Operating Cash Flow | 11.72M | 13.42M | 11.35M | 320.00K | 1.94M | 3.21M |
| Investing Cash Flow | -14.16M | -12.32M | -11.06M | -1.57M | -1.63M | -1.30M |
| Financing Cash Flow | 15.13M | -402.00K | 8.84M | -1.58M | -312.00K | -474.00K |
Austco Healthcare Limited Technical Analysis
Austco Healthcare Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$164.89M | 26.99 | 12.35% | ― | 39.98% | -30.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$119.74M | -26.79 | -4.28% | ― | 7.38% | 82.39% | |
41 Neutral | AU$830.45M | -22.71 | -44.49% | ― | 55.91% | 22.60% | |
41 Neutral | AU$73.35M | -5.22 | -31.98% | ― | 34.20% | -23.90% | |
40 Underperform | AU$84.39M | -11.89 | ― | ― | ― | ― | |
40 Underperform | AU$106.68M | -13.09 | -47.98% | ― | 700.00% | 26.88% |
Austco Healthcare Limited Corporate Events
Austco Healthcare Limited has announced the issuance of 2,159,408 Performance Rights under its Share Incentive Plan, with a performance period from July 2025 to June 2028. The vesting of these rights is contingent upon achieving specific EPS growth targets and indexed TSR benchmarks. Additionally, Austco plans to offer an additional 632,649 Performance Rights, pending shareholder approval at the upcoming AGM. This strategic move is likely aimed at aligning employee incentives with company performance, potentially enhancing Austco’s market position and shareholder value.
The most recent analyst rating on (AU:AHC) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has released a presentation for its FY 2025 roadshow, highlighting its commitment to growth through innovation. The presentation, authorized by the company’s Board, outlines the company’s strategic direction but does not constitute an offer for securities. The release emphasizes the company’s focus on innovation and its potential impact on operations and industry positioning, although it includes disclaimers regarding forward-looking statements and legal limitations.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has announced that its Annual General Meeting (AGM) for 2025 will be held virtually on October 29, 2025, utilizing the Computershare meeting platform. This decision follows the Treasury Laws Amendment allowing virtual AGMs, enabling shareholders to participate online by viewing presentations, voting, and posing questions. The meeting will address ordinary business, including the consideration of financial statements and a non-binding resolution on the remuneration report. The company has outlined voting restrictions for key management personnel and their closely related parties, ensuring compliance with the Corporations Act.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has issued 9,180,165 ordinary shares to the vendors of Amentco as part of the earnout agreement for Amentco’s acquisition, priced at $0.365 per share, totaling $3,350,760.79. Additionally, a cash payment of $5,026,141.19 was made to fulfill the company’s remaining earnout obligations, enhancing Austco’s strategic position in the healthcare communication sector.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has announced the quotation of 9,180,165 ordinary fully paid securities on the Australian Securities Exchange (ASX) as of September 23, 2025. This move is part of a previously announced transaction, potentially enhancing the company’s liquidity and market presence, which could positively impact its operations and stakeholders.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited announced a proposed issue of 9,180,165 ordinary fully paid securities, scheduled for September 23, 2025. This move is part of a placement or other type of issue, potentially impacting the company’s market positioning by increasing its capital base, which could be used for further development and expansion of its healthcare solutions.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited reported record revenues of $81.4 million for the fiscal year ending June 30, 2025, marking a 40% increase from the previous year. This growth was driven by both organic expansion and strategic acquisitions, with EBITDA rising by 62% to $13.0 million. The company has successfully integrated acquisitions like Teknocorp, Amentco, and G&S Technologies, which have expanded its capabilities and customer reach. Looking ahead, Austco plans to continue integrating new acquisitions, improve operating leverage, and sustain innovation through R&D investment, positioning itself for sustained growth in the healthcare communication and workflow solutions market.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has announced the issuance of 71,645 fully paid ordinary securities under an employee incentive scheme, which will be quoted on the ASX. This move is likely to strengthen employee engagement and align their interests with the company’s growth objectives, potentially enhancing Austco’s market position and operational efficiency.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited announced the release of 10,256,410 fully paid ordinary shares from voluntary escrow, which were initially issued as part of the acquisition of Amentco in May 2024. This release, scheduled for 29 September 2025, signifies a strategic move in the company’s acquisition strategy, potentially impacting its market positioning and shareholder interests.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has announced a change in the director’s interest, with Director James Brett Francis Burns acquiring an additional 59,264 ordinary shares through an on-market trade at $0.34 per share. This change reflects an increase in his direct holdings to 68,319 shares, while his indirect holdings remain at 1,400,282 shares. The acquisition of shares by a director may indicate confidence in the company’s future prospects, potentially impacting investor perceptions and market positioning.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has released its corporate governance statement for the financial year ending June 30, 2025, which has been approved by the board. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles and recommendations, including the establishment of a board charter and the accountability of the company secretary to the board. This disclosure is part of Austco’s commitment to transparency and effective governance, potentially enhancing its reputation and trust among stakeholders.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited reported a significant growth in its FY25 financial results, with revenues increasing by 40% to $81.4 million and EBITDA rising by 62% to $13.0 million. This growth was driven by both organic expansion and acquisitions, although the integration of these acquisitions slightly impacted gross margins. The company anticipates future margin improvements through operational efficiencies and supply chain enhancements. Despite increased overhead expenses due to acquisitions, Austco continues to invest in research and development, highlighting its commitment to innovation in the healthcare communication industry.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited reported a significant increase in revenue for the year ended 30 June 2025, with a 40% rise compared to the previous year, reaching $81.4 million. Despite the revenue growth, the company experienced a decrease in net profit after tax by 16.2% to $5.9 million, attributed to increased expenses and a contingent consideration expense. The overall comprehensive income saw a slight decline of 4.4%, reflecting the challenges faced in maintaining profitability amidst rising operational costs.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has announced the issuance of 106,207 fully paid ordinary securities under an employee incentive scheme. This move is part of the company’s strategy to motivate and retain its workforce, potentially impacting its operational efficiency and market competitiveness positively.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited has announced the issuance of 1,085,038 ordinary fully paid securities to be quoted on the ASX as part of an employee incentive scheme. This move is expected to strengthen the company’s operational capabilities and enhance its market positioning by aligning employee interests with corporate growth objectives.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.
Austco Healthcare Limited announced a significant financial performance for the year ending June 30, 2025, with a revenue increase of over 37% and EBITDA growth exceeding 54%. This growth was driven by both organic operations and strategic acquisitions, including the successful integration of Amentco Enterprise Group Pty Ltd and G&S Technologies Limited. The company funded these acquisitions through operating cash flows, maintaining a strong cash position. The strong performance of Amentco led to a higher-than-expected earn-out payment, impacting statutory net profit but not EBITDA. Austco’s CEO highlighted the transformative nature of FY25, emphasizing the company’s robust contracted revenue and strategic execution, positioning it confidently for FY26.
The most recent analyst rating on (AU:AHC) stock is a Buy with a A$0.45 price target. To see the full list of analyst forecasts on Austco Healthcare Limited stock, see the AU:AHC Stock Forecast page.